Search

Vivani Medical

Gesloten

1.36 -2.86

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.33

Max

1.3900000000000001

Belangrijke statistieken

By Trading Economics

Inkomsten

-147K

-6.8M

Werknemers

42

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+177.54% upside

Dividenden

By Acuity

Volgende Winsten

12 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

26M

103M

Vorige openingsprijs

4.22

Vorige sluitingsprijs

1.36

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 aug 2026, 23:51 UTC

RBA Meeting Minutes Release on August 25, 2026, Sparks Cautious Market Sentiment Amid Persistent Inflation and Economic Cooling in Australia.

22 aug 2026, 23:51 UTC

Macro News

Bitcoin is trading lower during Saturday's session, despite earlier rising above $70,000, amid ongoing geopolitical tensions and pressures in the bond market.

22 aug 2026, 23:41 UTC

Bitcoin and Ethereum decline as rising bond yields raise concerns over economic growth and investor sentiment shifts towards safer assets.

22 aug 2026, 23:41 UTC

Cryptocurrency Prices Drop Amid Rising Bond Yields and Geopolitical Tensions, Impacting Market Sentiment.

22 aug 2026, 23:41 UTC

Cryptocurrency Markets Decline Amid Rising Bond Yields and Economic Pressures, with Ethereum Down 3.9% and Bitcoin 1.7%.

22 aug 2026, 23:41 UTC

Bitcoin and Ethereum decline as rising bond yields and inflation concerns pressure risk assets amid mixed global market performance.

22 aug 2026, 23:41 UTC

U.S. Goods Trade Balance Expected to Show $99 Billion Deficit Amidst Rising Tariff Tensions with Canada

22 aug 2026, 23:41 UTC

Upcoming U.S. Retail Inventories Ex Autos Data Release on August 27, 2026, Expected to Impact Market Sentiment Amid Cautious Investor Outlook.

22 aug 2026, 23:41 UTC

U.S. Wholesale Inventories Expected to Rise 0.1% Amid Caution Over Economic Conditions and Market Volatility

22 aug 2026, 23:41 UTC

Canada's Current Account Deficit Expected to Widen to -5.5 Billion CAD Amid Trade Negotiation Uncertainties with the U.S.

22 aug 2026, 23:41 UTC

Terra is trading lower today, reversing three consecutive sessions of gains. The asset has declined significantly since Friday's close, with no specific news identified.

22 aug 2026, 23:31 UTC

US GDP Price Index QoQ 2nd Estimate on August 26 Forecasts 0.063% Increase Amid Rising Oil Prices and Optimistic Q3 Growth Outlook

22 aug 2026, 23:31 UTC

South Africa's Balance of Trade Data Set for Release Amidst Investor Optimism Following Recent Surplus Growth and Global Economic Pressures.

22 aug 2026, 23:31 UTC

U.S. Home Prices Expected to Rise 1.7% YoY Amid Mixed Economic Sentiment and Market Volatility

22 aug 2026, 23:21 UTC

Market braces for July 2026 PCE Price Index release, with a modest +0.1% increase forecast amid mixed inflation sentiment and external economic pressures.

22 aug 2026, 23:21 UTC

PCE Price Index Release on August 26, 2026: Key Inflation Indicator Amid Market Volatility and Fed Policy Concerns.

22 aug 2026, 23:21 UTC

U.S. Personal Income Expected to Rise 0.3% in August Amid Cautious Market Sentiment and Consumer Spending Concerns

22 aug 2026, 23:21 UTC

U.S. Personal Spending Forecasted to Rise 0.2% in August Amid Mixed Economic Signals and Inflation Concerns

22 aug 2026, 23:21 UTC

Core PCE Price Index MoM for July 2026 set to release on August 26, with a forecasted increase of 0.2%, amid rising oil prices and geopolitical tensions influencing market sentiment.

22 aug 2026, 23:21 UTC

U.S. Durable Goods Orders Ex Transportation Expected to Rise 0.5% Amid Economic Caution and Upcoming Market Influences

22 aug 2026, 23:21 UTC

U.S. Durable Goods Orders Expected to Rise 0.7% Amid Economic Volatility and Geopolitical Tensions, with Market Cautiously Optimistic Ahead of Jackson Hole Symposium

22 aug 2026, 23:21 UTC

U.S. GDP Growth Rate Expected at +1.5% for Q2 2026 Amid Optimistic Economic Indicators and Fed's Revised Forecast of +2.3% for Q3

22 aug 2026, 23:21 UTC

U.S. Corporate Profits Report for Q2 2026 Set to Release Amid Economic Uncertainty and Market Volatility on August 26.

22 aug 2026, 23:11 UTC

ECB Meeting Accounts Set for Release Amid Market Anticipation of Interest Rate Signals and Inflation Trends on August 27, 2026.

22 aug 2026, 23:11 UTC

Mexico's Trade Balance Expected to Show Continued Surplus Amid U.S.-Canada Negotiation Uncertainty Ahead of August 27 Data Release.

22 aug 2026, 23:11 UTC

Brazil's Unemployment Rate Set for Release Amid Optimistic Market Sentiment Following June Drop to 5.4%

22 aug 2026, 23:11 UTC

News

Ethereum is lower today, continuing a decline since Friday's close. Earlier, the asset reached a session low before recovering slightly.

22 aug 2026, 23:11 UTC

Correlated Moves

Avalanche is declining today, influenced by a drop in correlated asset Ethereum. The asset's recent strong performance contrasts with today's downturn during the session.

22 aug 2026, 23:11 UTC

News

Ethereum is lower during Saturday's session, reflecting a significant drop since Friday's close. The asset reached a session low earlier today.

22 aug 2026, 23:01 UTC

Macro News

The DAX 30 Index is declining after the U.S. imposed 50% tariffs on Canadian goods, worsening trade relations and impacting investor sentiment.

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Koersdoel

By TipRanks

177.54% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.83 USD  177.54%

Hoogste 4 USD

Laagste 3.5 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vivani Medical - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Operationele winst

$

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
help-icon Live chat